Traws Pharma (TRAW) Fundamental Analysis: Revenue, Earnings & Valuation

1.85 / 10

Underperform

Fundamentally, TRAW scores 1.9/10, indicating poor quality. Inventory turnover is moderate (53.1) while cost of sales is high (71.9%). Revenue growth is flat and current liabilities represent 20% of total liabilities. Interest coverage is adequate, but overall metrics suggest underperformance.

Analysis Checks(4/7)

Total operating revenue (YoY growth rate %)

Value0.00

Score1/3

Weight8.14%

1M Return-0.38%

Inventory turnover ratio

Value53.12

Score2/3

Weight23.68%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value20.38

Score1/3

Weight33.14%

1M Return-1.69%

Long-term debt to working capital ratio (%)

Value3.36

Score3/3

Weight-18.16%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value65.69

Score2/3

Weight24.07%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value0.00

Score1/3

Weight6.39%

1M Return-0.30%

Cost of sales ratio (%)

Value71.87

Score2/3

Weight22.75%

1M Return-1.13%

Is TRAW fundamentally strong?

TRAW scores 1.85/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -467.64% net margin, -2.60 P/E ratio, 2.92 P/B ratio, and 95.14% earnings growth, these metrics solidify its Underperform investment rating.